Kolexia
Chatellier Thierry Oncologie médicale
Chatellier Thierry
Oncologie médicale
Clinique Mutualiste De L'estuaire
Saint-Nazaire, France
46 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du poumon Carcinome pulmonaire à petites cellules Carcinomes Carcinome pulmonaire non à petites cellules Tumeurs colorectales Carcinome épidermoïde Néphrocarcinome Carcinome épidermoïde de la tête et du cou Tumeurs épidermoïdes

Collaborateurs

Voir plus
Saliou Marie-Gabrielle
Saliou Marie-Gabrielle
Clinique Mutualiste De L'estuaire, Saint-Nazaire, France
Delecroix Valerie
Delecroix Valerie
Clinique Mutualiste De L'estuaire, Saint-Nazaire, France
Drouet Franck
Drouet Franck
Clinique Mutualiste De L'estuaire, Saint-Nazaire, France
Bennouna-Louridi Jaafar
Bennouna-Louridi Jaafar
Hôpital Foch, Suresnes, France

Industries

Voir plus
A+A
8 collaboration(s)
Dernière en 2021
IQVIA
6 collaboration(s)
Dernière en 2020
EXAFIELD
5 collaboration(s)
Dernière en 2021
BMS
4 collaboration(s)
Dernière en 2020

Dernières activités

Voir plus
EORTC-SPECTA Arcagen study, comprehensive genomic profiling and treatment adaptation of rare thoracic cancers.
NPJ precision oncology   16 février 2024
REAL-MOOV-LUNG: Real Life Prospective Multicentric Study Evaluating the Clinical and Organisational Impact of Moovcare® Lung Connected Medical Device in Lung Cancer Patients : REAL-MOOV-LUNG
Essai Clinique (Institut Curie)   19 décembre 2023
A Multicenter Study Assessing the Real-World Use and Effectiveness of First-Line Chemotherapy Plus Immunotherapy in Advanced Small-Cell Lung Cancer (SCLC) Patients.
Clinical lung cancer   23 novembre 2023
SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access
Essai Clinique (Organisation européenne pour la recherche et le traitement du cancer)   02 novembre 2023
Correction to: Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50.
Cancer immunology, immunotherapy : CII   22 mai 2023
Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 ≥ 50.
Cancer immunology, immunotherapy : CII   24 janvier 2023
Predictive value of vascular endothelial growth factor polymorphisms for maintenance bevacizumab efficacy in metastatic colorectal cancer: an ancillary study of the PRODIGE 9 phase III trial.
Therapeutic advances in medical oncology   26 décembre 2022
Daily practices in chemotherapy for advanced gastric or gastroesophageal junction adenocarcinoma: METESTOMAC French prospective cohort.
Cancer medicine   16 novembre 2022
FRAIL-IMMUNE: Multicenter Prospective Single Arm Phase II Study Evaluating Efficacy & Safety of Durvalumab With Carboplatin/Paclitaxel as First Line Treatment in Patients With Recurrent/Metastatic SCCHN Not Eligible to Standard Chemotherapy
Essai Clinique (Centre Léon-Bérard)   03 octobre 2022
66P Incidence and impact on survival of venous thromboembolic events in patients with advanced non-small cell lung cancer receiving pembrolizumab as first-line of treatment
European Lung Cancer Congress (ELCC) 2022, 30 March-2 April 2022   01 avril 2022